Tegoprubart beats tacrolimus at preserving kidney function in phase 2 transplant trial
Start here
The phase 2 BESTOW trial tested tegoprubart, an anti-CD40L antibody, against tacrolimus, the standard immunosuppressant, in patients receiving a first kidney transplant. Results showed tegoprubart preserved transplanted kidney function better than tacrolimus and significantly improved patient-reported quality of life. Tacrolimus, while effective at preventing rejection, is known to harm kidney function over time, so a regimen that protects the graft while maintaining immunosuppression would address a long-standing problem in transplant medicine. The findings, reported in October 2026, support the candidate as a potential tacrolimus replacement, though further trial results and regulatory steps remain ahead.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- medicalxpress.comPickTegoprubart preserves kidney function better than tacrolimus in first-time transplant patients, trial suggests
The phase 2 BESTOW clinical trial showed that the anti-CD40L antibody tegoprubart preserved transplanted kidney function better than the standard of care tacrolimus in patients receiving a first kidney transplant, and significantly improved patient-reported quality of life.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 24 03:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.